Ga68 NETSPOT Radiopharmaceuticals Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA

Solicitation Number / RFQ 36C24425Q0362 NETSPOT Ga68 Dotatate Corporal Michael J. Crescenz VA Medical Center (CMC VAMC) This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with the format in FAR subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

This Solicitation is being issued as Request for Quotation (RFQ) 36C24425Q0362. The government anticipates awarding one 12-month firm-fixed monthly price order resulting from this solicitation. The ordering Period has the start date of June 04, 2025, through June 03, 2026. This solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2025-03 (01/17/2025) and can be found at FAR | Acquisition.GOV.

The North American Industrial Classification System (NAICS) code for this procurement is 325412 with a small business size standard of 1300 employees. This solicitation is Small Business Set-Aside. This solicitation requires registration with the System for Award Management (SAM) prior to award, pursuant to applicable regulations and guidelines. Registration information is at www.sam.gov. Confirmation of SAM registration will be validated prior to award.

Statement of Work Summary: The Corporal Michael J. Crescenz VA Medical Center (CMC VAMC) requires a vendor licensed by the Nuclear Regulatory Commission to provide the radiopharmaceutical NETSPOT and calibration sources for the Nuclear Medicine Service. This radiopharmaceutical is required for imaging procedures. The Calibration sources are required for equipment quality control testing. This product is a patented drug kit for the preparation of gallium Ga 68 dotatate for injection. It is used for PET imaging for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.